| Literature DB >> 25492359 |
Yucel Altundal1, Gizem Cifter2, Alexandre Detappe3, Erno Sajo2, Panagiotis Tsiamas4, Piotr Zygmanski4, Ross Berbeco4, Robert A Cormack4, Mike Makrigiorgos4, Wilfred Ngwa5.
Abstract
We predict, for the first time, that by using United States Food and Drug Administration approved concentrations of cisplatin, major radiosensitization may be achieved via photoelectric mechanism during concomitant chemoradiotherapy (CCRT). Our analytical calculations estimate that radiotherapy (RT) dose to cancer cells may be enhanced via this mechanism by over 100% during CCRT. The results proffer new potential for significantly enhancing CCRT via an emerging clinical scenario, where the cisplatin is released in-situ from RT biomaterials loaded with cisplatin nanoparticles.Entities:
Keywords: Brachytherapy; Chemoradiotherapy; Cisplatin nanoparticles; Dose enhancement; Radiotherapy
Mesh:
Substances:
Year: 2014 PMID: 25492359 PMCID: PMC4492437 DOI: 10.1016/j.ejmp.2014.11.004
Source DB: PubMed Journal: Phys Med ISSN: 1120-1797 Impact factor: 2.685